Laronde has developed a programmable RNA platform utilizing Endless RNA™ technology and proprietary nanoparticles to express diverse proteins within the body for therapeutic applications. This approach aims to enhance the treatment of various diseases, including oncology and rare conditions, by providing long-lasting and targeted protein expression.
Funding
Funding not disclosed
BMFounders
Product
Problem
Current protein therapies often require frequent, high-dose administrations to maintain therapeutic levels, leading to potential off-target effects and high treatment burdens for patients. Traditional mRNA therapies face limitations in duration of expression and delivery efficiency, hindering their effectiveness in treating chronic diseases.
Solution
Sail Biomedicines is developing a programmable RNA platform that utilizes Endless RNA™ (eRNA™) technology and proprietary Natural NanoParticles (NNPs) to enable sustained and targeted protein expression within the body. The eRNA is a synthetic, translatable, and stable circular RNA designed for long-lasting expression of diverse proteins. NNPs, derived from natural sources, are engineered to efficiently deliver eRNA to specific cells and tissues, offering unique tropism and the potential for re-dosing. This integrated platform aims to create fully programmable medicines with improved performance and broad applicability across various therapeutic areas.
Target Audience
The primary target audience includes patients with oncology, metabolic diseases, infectious diseases, rare diseases, and immunology conditions, as well as pharmaceutical companies seeking novel therapeutic modalities.
Features
- Endless RNA™ (eRNA™): A circular RNA technology for sustained protein expression.
- Natural NanoParticles (NNPs): Proprietary nanoparticles for targeted delivery of eRNA.
- AI-powered design: Utilizes AI algorithms for integrative design of RNA medicines.
- Rapid prototyping and testing bioplatform: Enables efficient development and optimization of RNA therapies.
- Potential for unique tropism: NNPs can be engineered to target specific cells and tissues.
- Wide range of routes of administration: Platform supports various delivery methods.
- Ability to re-dose: NNPs allow for repeated administration of eRNA.